Expansion of CD4+CD25+ helper T cells without regulatory function in smoking and COPD by Roos-Engstrand, Ester et al.
RESEARCH Open Access
Expansion of CD4
+CD25
+ helper T cells without
regulatory function in smoking and COPD
Ester Roos-Engstrand
1*, Jamshid Pourazar
1, Annelie F Behndig
1, Anders Bucht
1,2 and Anders Blomberg
1
Abstract
Background: Regulatory T cells have been implicated in the pathogenesis of COPD by the increased expression of
CD25 on helper T cells along with enhanced intracellular expression of FoxP3 and low/absent CD127 expression
on the cell surface.
Method: Regulatory T cells were investigated in BALF from nine COPD subjects and compared to fourteen
smokers with normal lung function and nine never-smokers.
Results: In smokers with normal lung function, the expression of CD25
+CD4
+ was increased, whereas the
proportions of FoxP3
+ and CD127
+ were unchanged compared to never-smokers. Among CD4
+ cells expressing
high levels of CD25, the proportion of FoxP3
+ cells was decreased and the percentage of CD127
+ was increased in
smokers with normal lung function. CD4
+CD25
+ cells with low/absent CD127 expression were increased in smokers
with normal lung function, but not in COPD, when compared to never smokers.
Conclusion: The reduction of FoxP3 expression in BALF from smokers with normal lung function indicates that the
increase in CD25 expression is not associated with the expansion of regulatory T cells. Instead, the high CD127 and
low FoxP3 expressions implicate a predominantly non-regulatory CD25
+ helper T-cell population in smokers and
stable COPD. Therefore, we suggest a smoking-induced expansion of predominantly activated airway helper T cells
that seem to persist after COPD development.
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Introduction
Chronic obstructive pulmonary disease (COPD) is char-
acterized by progressive airway obstruction and airway
inflammation. Tobacco smoking is the main risk factor
for COPD. Smoking causes an inflammatory response in
all smokers but only 50 percent develop COPD [1].
Increased numbers of neutrophils, macrophages and T
lymphocytes have been found in the lungs of COPD
patients [2,3]. A relationship has been shown between
the number of cytotoxic CD8
+ T-cells and a decline in
lung function in patients with COPD [4,5] suggesting a
role for these cells in the pathogenesis of COPD. The bal-
ance between CD4
+ helper T cells and CD8
+ cytotoxic
T-cells is altered in the lungs of COPD patients, which
results in a decline in the CD4/CD8 ratio [4]. Both CD4
+
and CD8
+ cells have been shown to be more activated in
both smokers and in subjects with COPD [6]. CD25 is a
constitutively expressed activation marker and CD4
+
cells with “bright” or “high” expression of CD25
+ have
been suggested to be regulatory T cells, previously
defined as suppressor T cells [7]. Their function is to
suppress immune responses by the secretion of soluble
inhibitory mediators, such as interleukin 10, or through
direct cell-to-cell contact. The role of regulatory
T cells in COPD is not well-known, but Smyth et al
have reported that long-term cigarette smoking
increases airway regulatory T cell numbers, in terms of
CD4CD25
bright cells [8]. In contrast, two other studies
reported decreased levels of regulatory T-cells in subjects
with emphysema and COPD compared to healthy con-
trols [9,10].
However, CD25
bright is not a definite marker of regula-
tory T cells [11]. Transcription factor fork head box P3,
FoxP3, is considered a unique intra-nuclear regulatory
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immune dysfunction polyendocrinopathy enteropathy
X-linked syndrome, IPEX, but also other autoimmune
conditions such as diabetes, thyreoditis and inflammatory
bowel diseases [12]. Recently, absent or low expression of
the IL-7a receptor (CD127
dim) has been reported as
another unique marker for regulatory T cells [13]. As
CD127 is an extracellular marker, it is more easily ana-
lysed compared to FoxP3. Studies have shown that
CD127 is down-regulated on all human T cells after acti-
vation [14]. In a recent study, we have shown that airway
T cells are highly activated in COPD as indicated by
increased expression of CD69 and HLA-DR [6]. In addi-
tion, CD4
+ cells express high levels of CD25 in COPD
and smokers, suggesting the presence of regulatory
T-cells [6]. It is of importance to verify and evaluate reg-
ulatory T cells in COPD in more detail, as these cells
m a yp l a yar o l ei nt h ep a t h o g e n e s i so fC O P D ,a ss u g -
gested by Barceló [10]. The aim of this study was there-
fore to identify airway regulatory T cells in smokers and
individuals with COPD, using flow cytometric analysis of
CD127 and FoxP3 and their relation to CD25 expression.
Materials and methods
Subjects
Nine patients with COPD (four ex-smokers and five
smokers), fourteen smokers with normal lung function
(defined as smokers with normal dynamic spirometry,
i.e. FEV1 and FVC values within 80-120% of predicted
value) and nine healthy never-smokers were recruited,
(table 1). All COPD subjects and smokers with normal
lung function had a smoking history of at least ten
pack-years. Current smokers were not allowed to smoke
for at least 12 hours prior to bronchoscopy. The sub-
jects were not allowed to have any other medical condi-
tion apart from COPD.
The COPD patients did not receiv any treatment with
inhaled corticosteroids or oral anti-inflammatory drugs
during at least four weeks prior to study start and
neither regular long-acting b2-agonists nor long-acting
anti-cholinergic drugs were allowed within two weeks
prior to bronchoscopy. Short-acting b2-agonists and/or
anti-cholinergic drugs were used on demand. All sub-
jects were non-atopic and free from symptomatic airway
infection within a six week-period prior to the study.
None had a history of chronic bronchitis or frequent
infectious exacerbations. All COPD patients had a post
bronchodilator FEV1/FVC of less than 70% and were
not reversible. Informed consent was obtained from all
volunteers after verbal and written information and the
study was approved by the local Ethics Review Board at
Umeå University, Sweden, and performed according to
the declaration of Helsinki.
Methods
Spirometry
Dynamic spirometry (FVC and FEV1)w a sp e r f o r m e d
post-bronchodilatation using a Vitalograph spirometer
(Vitalograph Ltd., Buckingham, UK), as outlined pre-
viously [6].
Bronchoscopy
Before bronchoscopy atropine was given subcutaneously.
Topical anaesthesia of the airways was obtained with
lidocaine. All subjects were examined in the supine posi-
tion using an Olympus BF IT160 video bronchoscope
(Olympus, Tokyo, Japan). Bronchoalveolar lavage (BAL)
was performed by infusing three aliquots of 60 ml of
sterile sodium chloride (NaCl), pH 7.3 at 37°C that were
gently sucked back after each infusion and pooled into a
container placed in iced water. The recovered fluid was
immediately transported to the laboratory for analysis.
Table 1 Demographics and spirometry values
Never-smokers
n=9
Smokers
n=1 4
COPD
Ex-smokers
n=4
COPD
Smokers
n=5
Male:Female 5:4 7:7 4:0 0:5
Age 65 ± 5.2 60 ± 6.6 67 ± 2.1 61 ± 2.4
Smoking (pack years) 0 (0-0) 30 (20-44) 50 (44-52) 46 (35-65)
COPD stage
(GOLD)
+
NA NA 2 and 3 2 and 3
FEV1/FVC %
Pre bronchodilatation
77 (74-83) 78 (75-82) 62 (60-67) 60 (56-67)
FEV1/FVC %
Post bronchodilatation
NA 78 (77-81) 64 (62-67) 60 (59-66)
FEV1 % of predicted Pre bronchodilatation 101 (89-110) 112 (104-120) 53 (40-64) 53 (47-66)
FEV1 % of predicted Post bronchodilatation NA 114 (108-119) 63 (52-67) 60 (55-68)
Data are shown as mean ± standard deviation for age, median and inter quartile range for all others. FEV1: Forced expiratory volume in one second; FVC: Forced
vital capacity. NA: not applicable. + http://www.goldcopd.org. In the ex-smoking COPD patients, the smoking cessation was more than five years prior to study
inclusion.
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BAL -lymphocyte subsets were determined using flow
cytometry. BAL cells were centrifuged and diluted to a
final concentration of 10
6 cells/ml. For each test, 10 μlo f
antibody solution was added to 200 μlo fc e l ls u s p e n s i o n
and allowed to bind for 30 minutes at 4°C in darkness.
Red blood cells were lysed with 2 ml FACS
™ Lysing solu-
tion (Becton Dickinson Immunocytometry Systems, San
Jose, CA, USA) for 10 minutes at room temperature. The
remaining cells were then washed by adding PBS to the
tubes and centrifuged at 4°C for 10 minutes, 300 g and
repeated once. Cells were thereafter fixed with 500 μlC e l l -
FIX
™ (Becton Dickinson Immunocytometry Systems, San
Jose, CA, USA) before analysis using a FACSCalibur
™
(Becton Dickinson) flow cytometer. The lymphocyte
population was gated on their physical characteristics in a
region according to their characteristic forward scatter
(FCS) and side scatter (SSC) profiles, as previously
reported [6]. 3,000 total events were collected in CD3
+
gate per sample.
To identify CD3
+,C D 4
+,C D 2 5
+ and CD127
+ cells, the
cells were stained with Allophycocyanin (APC) conjugated
anti-human CD3, fluorescein isothiocyanate (FITC) conju-
gated anti-human CD4, phycoerytrin-Cy5 (PE Cy5) conju-
gated anti-human CD25 and phycoerytrin (PE) conjugated
anti-human CD127 in the same test tube (Becton Dickin-
son, San Jose, CA, USA). The percentage of different cell
types was counted out of gated CD3
+ lymphocytes and
furthermore out of gated CD4
+.C D 2 5
bright cells were
quantified as previously described [8,15]. Analyses of
CD127
-&dim are performed as shown in Figure 1.
Intracellular staining of FoxP3 was conducted according
to the recommended procedure obtained from eBioscience
(San Diego, CA, USA). Cells were permeabilised with
eBioscience FoxP3 Staining Buffer Set at 4°C for 30 min-
utes. By adding permeabilisation buffer to the tubes, cells
were washed and centrifuged at 4°C for 10 minutes, 300 g.
This washing procedure was performed twice. 10 μlo f
antibody solution was added to the cell suspension and
allowed to bind for 30 minutes at 4°C in darkness. The
cells were washed twice by adding permeabilisation buffer
to the tubes and centrifuged at 4°C for 10 minutes, 300 g
and 300 μl of PBS was added. To identify CD3
+,C D 4
+ and
CD25
+ cells, the cells were stained with same antibodies as
in the extracellular staining. To obtain FoxP3
+ cells, phy-
coerytrin (PE) conjugated anti-human FoxP3 was used in
the same test tube. The percentage FoxP3 was determined
out of gated CD3
+ and CD4
+ lymphocytes.
Statistical analysis
Flow cytometry data were acquired and analysed using
CellQuest Software (Becton Dickinson). Differences
between three groups were tested using Kruskal-Wallis
test and a p-value of less than 0.05 was considered signif-
icant. If the Kruskal-Wallis test indicated significance,
the Mann-Whitney U-test was used for post-hoc analysis
for comparison between two groups, with corrections of
p-values according to Bonferroni (a p-value less than
0.017 was considered significant). Whilst the number of
COPD patients was small, the ex-smoking COPD group
w a sc o m p a r e dt ot h es m o k i n gC O P Dg r o u p ,u s i n g
Mann-Whitney U-test. Here, a p-value of less than 0.05
was considered significant.
Results
The BAL recovery in subjects with COPD was (37%; 29-
52), (median; inter quartile range) in smokers with normal
lung function (53%; 49-61) and in never-smokers (50%;
34-64).
Smokers with normal lung function had increased
total leukocyte numbers in BAL compared to never-
smokers. Among leukocytes, the macrophage numbers
Figure 1 Flow cytometry analysis of CD127 expression on BAL CD4
+ T cells. Firstly, lymphocytes were gated in FSC and SSC. Secondly, CD4
+ cells were gated in the histogram. CD25 and CD127 expression on the gated CD4 cells were analyzed in a dot plot. The grey area indicates
CD25
+CD127
dim population.
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increased in smokers with normal lung function, com-
pared with COPD patients (table 2).
To examine whether the difference in airway inflamma-
tion between COPD patients and smokers with normal
lung function was due to smoking habits, the group of
COPD patients was divided into current smokers and ex-
smokers. This subgroup analysis showed that smoking
COPD patients had increased BAL macrophage numbers
compared to ex-smokers (table 2).
The median fluorescence intensity, MFI, were
enhanced in smokers with normal lung function and in
COPD, compared to never-smokers (Figure 2). The per-
centages of CD4
+CD25
+ (data not shown) and CD4
+CD25
bright (Figure 2) cells were enhanced in smokers
with normal lung function, compared to never-smokers
while the percentage of CD4
+FoxP3
+ and CD4
+CD127
+
cells was unchanged (Figure 3a and 3b). There were no
significant difference in CD4
+CD25
+ cells between
COPD patients and the other two groups. Among CD4
+
T cells expressing CD25, smokers with normal lung func-
tion had significantly decreased percentage of FoxP3
compared to never-smokers. CD127 expression on CD4
+
T cells expressing CD25 was enhanced in subjects with
COPD and smokers with normal lung function, com-
pared to never-smokers (Figure 3). Ex-smoking COPD
patients expressed decreased percentage of CD127
+ cells
in BALF compared to smoking COPD patients (Figure
3d). The expression of CD127
-&dim on CD4
+CD25
+ T
cells was increased in smokers with normal lung func-
tion, compared to non-smokers (Figure 4).
Discussion
It has been suggested that regulatory T cells are important
in the pathogenesis of COPD [8,10]. Recently published
data have shown increased CD4
+CD25
bright cells in the air-
ways of subjects with COPD and smokers with normal
lung function compared to never-smokers, suggesting the
presence of regulatory T cells [6,8]. In contrast, Barceló et
al reported decreased percentages of CD4
+CD25
+ in
patients with COPD compared to smokers with normal
lung function [10] and Lee et al reported similar findings
in patients with emphysema [9]. Recently, we found a
decreased proportion of CD4
+CD25
bright cells in ex-smok-
ing subjects with COPD compared to smoking COPD
subjects [6]. However, despite more than five years after
smoking cessation, the proportion of these cells was not
normalized, suggesting a smoke-induced upregulation of
CD4
+CD25
bright cells. Smoking habits in the other two stu-
dies [8,10] were not clearly defined, which makes a full
comparison between the studies difficult. CD4
+CD25
bright
cells have been suggested to have regulatory features as
key immunomodulators. In smokers who maintain normal
lung function, it has been implied that the upregulation of
regulatory T cells would restrain cigarette smoke-induced
inflammatory activation and, thus, the development of
COPD [10]. In contrast, in smokers who develop COPD,
the T regulatory response is supposed to be inappropriate,
which enables an uncontrolled progress of the immunor-
eaction, involving the activation of T cells into a cytotoxic
phenotype. This further supports a potential involvement
of the acquired immune response in the pathogenesis of
COPD.
To further evaluate the role of regulatory T cells in
COPD and to clarify whether CD4
+CD25
bright cells
really have regulatory properties, more specific biomar-
kers are needed. The transcription factor FoxP3 is
known to be highly expressed in regulatory T cells,
whereas the cell surface marker CD127 is supposed to
be low or absent on regulatory T cells [16,17]. Investiga-
tions of these markers in COPD are rare and, to our
knowledge, this is the first study addressing CD127
expression on BAL cells from smokers and subjects with
COPD.
Table 2 Differential cell count of leukocytes in BAL fluid, given in number cells/ml*10
4
Never smokers
(NS)
n=9
Smokers
(S)
n=1 4
COPD
n=9
p COPD
ex-smokers
n=4
COPD
smokers
n=5
p
Total
leukocytes
21 (13-26) 41 (34-52) 25 (18-37) P < 0.001
NS vs S
20 (10-26) 29 (22-52) NS
Macrophages 19 (12-23) 37 (31-48) 22 (17-33) P < 0.001
NS vs S P <
0.014
S vs COPD
19 (9.6-22) 27 (20-42) P < 0.05
COPD ex-s vs COPD
s
Neutrophils 0.2 (0.045-0.31) 0.49 (0.23-1.1) 0.19 (0.06-0.93) NS 0.36 (0.04-1.07) 0.19 (0.07-5.2) NS
Lymphocytes 1.7 (1.1-2.2) 2.3 (1.5-3.9) 1.5 (0.90-2.8) NS 1.5(0.8-2.2) 1.5 (0.7-4.1) NS
Eosinophils 0.08 (0-0.54) 0.05 (0-0.3) 0.06 (0.01-0.66) NS 0.015 (0.00-
0.52)
0.47 (0.05-
0.96)
NS
Mast cells 0.06 (0.005-0.12) 0.06 (0.03-
0.10)
0.03 (0.005-
0.065)
NS 0.005 (0.00-
0.04)
0.04 (0.02-
0.10)
NS
Data are given as median and IQR.
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Page 4 of 8Figure 2 Flow cytometry analyses of BAL T cells of never-smokers (NS), smokers with normal lung function (S) and COPD.C D 4
+CD25
bright are given as percent of gated CD3 (a). CD25
+ cells out of CD4
+ cells are given as median fluorescence intensity, MFI (b). Significance
levels are noted as ** p < 0.01, *** p < 0.001. Data are given as median and IQR.
Figure 3 Flow cytometry analyses of BAL T cells from never-smokers (NS), smokers with normal lung function (S) and COPD subjects.
The proportion of CD4
+ T cells expressing FoxP3 (a) or CD127 (b) are given as percent of total T cells (CD3
+). Percentage of FoxP3
+ (c) or
CD127
+ (d) among CD4
+ T cells expressing CD25. The CD127
+ population includes the CD127
dim cells. Within the COPD group, ● indicates ex-
smokers and Δ smokers. Significance levels are noted as ** p < 0.01 and *** p < 0.001. COPD smokers have increased proportions CD127/CD25
among CD4
+ cells compared to COPD ex-smokers (p = 0.027) and to never-smokers (p = 0.003). Data are given as median and IQR.
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asthma, gastric cancer and glioma [13,16,18]. Expression
of CD25 and CD127 on CD4
+ cells has been suggested to
discriminate between regulatory and activated T cells
[17]. FoxP3 is strongly expressed in CD25
bright cells,
whilst CD127 is down-regulated on these cells. CD127
expression is shown to be inversely associated with
FoxP3 and suppressive function of human CD4
+ regula-
tory T cells in peripheral blood [14]. In the present study
of BAL T cells, a similar pattern was found supporting an
inverse association between FoxP3 and CD127 expres-
sion also on BAL T cells (Figure 3c, d).
CD25 is of importance in mediating immune tolerance
and protection from autoimmune disease [19]. As indi-
cated above, CD25
bright expression on CD4
+ cells is usually
implied as regulatory T cells. The present study shows that
an increased percentage of of CD4
+ CD25
bright cells is
associated to current smoking (Figure 2a) and that
increased cell surface expression of CD25, expressed as
median fluorescence intensity, is associated to both cur-
rent smoking and COPD (Figure 2b). Even though the
number of patients in the present study is rather small,
the data are consistent with previously published results
[6].
When it comes to the proportion of CD127
+ helper T
cells among CD3
+ cells in BAL fluid, there was no dif-
ference between the three groups (Figure 3b). However,
in subjects with COPD and smokers with normal lung
function, the expression of CD127
+/CD4
+CD25
+ cells
was increased compared to never-smokers (Figure 3d).
When COPD subjects were divided into smokers and
ex-smokers, we observed that smokers had increased
proportions of CD127 on CD4
+CD25
+ cells compared
to ex-smokers (Figure 3d). The group of ex-smoking
COPD subjects is small, yet the present data imply that
tobacco smoking may induce an activation of airway
CD4
+ cells, in terms of increased CD127 expression and
that the CD127 expression appears to decline after
smoking cessation. Despite more than five years since
smoking cessation, the expression of CD127 among the
CD25 helper T cells tended to be higher in COPD
patients compared to never-smokers, indicating a pro-
longed immune activation.
No differences were found between the groups in helper
T cells expressing FoxP3
+ (Figure 3a). Among CD25
expressing helper T cells, the percentage of FoxP3
+ was
decreased in smokers compared to never-smokers. The
data suggest that a large proportion of CD4
+CD25
+ cells
in smokers do not express FoxP3 and, thus, have not a
regulatory T cell function. Compared to smokers and
non-smokers, a decrease in the expression of FoxP3 has
been found in the smaller airways in COPD, whereas
FoxP3 expression was increased in large airways in both
smokers and subjects with COPD [20]. Another study
reported increased regulatory T cell numbers in lymphoid
follicles and bronchial tissue in subjects with moderate
COPD [21]. Within the lung tissue, regulatory T cells
expressing FoxP3 seem to be more abundant in larger air-
ways compared to smaller airways. However, the role for
FoxP3 in regulating the immune defence in different
r e g i o n so ft h el u n g si ns m o k i n ga n dC O P Dn e e d st ob e
further elucidated.
CD25
+CD127
dim cells are suggested to have immunore-
gulatory properties, whilst CD25
+CD127
bright have not
[17]. Here, the proportion of CD4
+CD25
+ with low or
absent expression of CD127 was increased in smokers
with normal lung function compared to non-smokers.
However, from our data (Figure 4), it appears that the
smokers might be divided into two subpopulations, one
with increased CD127
-&dim on CD4
+CD25
+ cells and one
subpopulation with unchanged CD127
-&dim expression,
suggesting an increased presence of regulatory T cells in
some “healthy” smokers. Based on the present data, we
hypothesise that, within the group of smokers with normal
lung function, there may be subjects with insufficient
expansion of regulatory T cells, who will be at risk for
developing COPD [1]. If this was the case, it would be pos-
sible to distinguish between smoking subjects with differ-
ent susceptibility to develop COPD. This issue needs to be
addressed in future prospective studies. It cannot be
excluded that T-lymphocytes isolated from peripheral
blood or other lung compartments, such as bronchial
mucosa or peripheral lung tissue, may show different phe-
notypic characteristics compared with BAL-cells. It has
Figure 4 Flow cytometry analysis of CD127 expression on BAL
T cells from never-smokers (NS), smokers with normal lung
function (S) and COPD. The combined CD127
- and CD127
dim
populations are given as percent of gated CD25
+CD4
+ cells. Among
the COPD group, ● indicates ex-smokers and Δ smokers.
Significance levels are noted as ** p < 0.01 Data are given as
median and IQR.
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T regulatory cells in COPD compared to smokers and
healthy subjects [21].
The COPD subjects included in this study were clini-
cally stable, i.e. with no history of recurrent infectious
exacerbations and in no need of regular medications,
apart from short acting bronchodilators on demand.
Also, the ex-smoking COPD subjects stopped smoking
more than five years prior to study inclusion, whereas all
smokers with normal lung function were current smo-
kers, with at least a smoking history of ten pack years.
The differential cell count confirms previously pub-
lished data [6]. Macrophages were increased in smokers
with normal lung function and in smoking patients with
COPD. This is not surprising as macrophages play a key
role in the inflammatory response to noxious particles
and gases, such as tobacco smoke exposure. The lack of
increase in neutrophils in the COPD subjects further
implies that these subjects were without any history of
bronchitis or frequent infectious exacerbations. There
was no difference in lymphocyte numbers between the
three groups; the difference was within the lymphocyte
population, mainly related to the T lymphocyte subtypes.
In conclusion, we demonstrate that smoking subjects
with COPD have increased proportions of CD127
+ helper
T cells in the airways. Smoking cessation may reduce the
proportion of these cells but this has to be confirmed in
longitudinal studies. Thesed a t at h e r e f o r ei n d i c a t et h e
expansion of a T cell population without a regulatory
function, which may contribute to the persistent cyto-
toxic T cells responses previously reported in COPD.
However, a fraction of smokers without clinical signs of
COPD had an increased population of helper T cells with
low or absent CD127 expression, suggesting the presence
of regulatory T cells that potentially can modulate the
smoke-induced immune responses. Whether such a T
cell population would play a role in the protection of
COPD development in smokers remains to be elucidated.
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